Evidence map›Paper›PMID 30891620›Full record

ArticleRheumatology international2019

ESSDAI activity index of the SJÖGRENSER cohort: analysis and comparison with other European cohorts.

José Rosas, Carlos Sánchez-Piedra, Mónica Fernández-Castro, José Luis Andreu, Víctor Martínez-Taboada, Alejandro Olivé, SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Activity and Damage Indices for Sjögren's Disease.Journal of clinical medicine · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

José RosasRheumatology Department, Hospital Marina Baixa, Villajoyosa, Alicante, Spain. j.rosas.gs@gmail.com.ORCID http://orcid.org/0000-0001-5179-9674
Carlos Sánchez-PiedraResearch Unit, Spanish Society of Rheumatology, Madrid, Spain.ORCID http://orcid.org/0000-0001-5420-7347
Mónica Fernández-CastroRheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.ORCID http://orcid.org/0000-0003-4081-2751
José Luis AndreuRheumatology Department, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.ORCID http://orcid.org/0000-0002-6002-1239
Víctor Martínez-TaboadaRheumatology Department, Hospital Marqués de Valdecilla, Santander, Spain.ORCID http://orcid.org/0000-0003-2916-8491
Alejandro OlivéRheumatology Department, Hospital Germans Trias i Pujol, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6707-8043
SJÖGRENSER Group, part of the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of the study was to assess the ESSDAI index characteristics in the SJÖGRENSER cohort (Spanish Rheumatology Association's registry of patients with Primary Sjögren Syndrome [PSS]). SJÖGRENSER is a prospective multicentric study on a cohort of Spanish patients with PSS who meet the 2002 American-European consensus from rheumatology units. 298 variables were studied in patients for the inclusion of the study from an anonymous list from each department. The ESSDAI (EULAR Sjögren's syndrome disease activity index) includes 12 domains and measures systematic activity in PSS patients. Each domain is divided into 3-4 levels, (0: no activity; 1: low activity; 2: moderate activity; 3: high activity) and is attributed a weight. Each domain score is obtained by multiplying the activity level by the weight assigned. According to ESSDAI: low activity < 5; moderate activity 5-13, and high activity ≥ 14. ESSDAI was compared between several European PSS cohorts (EULAR, ASSES, GEAS, GRISS, Ducth). 437 patients were included from 33 Spanish rheumatology units. 95.2% were women with a median age of 58.63 years [p25-p75: 50.02-67.98 years] and average PSS evolution of 10.4 years (6-16 years). ESSDAI median on entering the study was 2 (0-4). 31% of patients had ESSDAI 0; low activity 49%, moderate activity 15%, and high activity 5%. Those with greater activity were the joint, haematological and biological domains, whereas the lung was the most affected organ with pleural and parenchymatous involvement. Unlike other European cohorts, the initial SJÖGRENSER cohort was characterised by low-zero systemic activity in 80% of patients, which differentiates it from other cohorts and provides a prospective study opportunity.

Indexed as

AgedAntirheumatic AgentsCohort StudiesEuropeFemaleHumansMaleMiddle AgedProspective StudiesRegistriesSeverity of Illness IndexSjogren's SyndromeSpainAntirheumatic AgentsCohort studyESSDAIPrimary Sjögren syndromeSJÖGRENSER

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.